Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Threshold Pharmaceuticals Inc announces TH-302 Data at 55th annual meeting of the American Society of Hematology


Sunday, 8 Dec 2013 10:00am EST 

Threshold Pharmaceuticals Inc:Says that clinical data from two early-stage trials of TH-302, its investigational hypoxia-targeted drug, will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH).Says that results from the dose escalation component of a Phase 1/2 clinical trial of TH-302 in combination with dexamethasone in patients with relapsed and/or refractory multiple myeloma will be presented in a poster session on Dec. 8 evening.Says that courteen patients initiated therapy, all having received 3 to 11 prior treatments (median of 6.5) and all having received a regimen containing Velcade (bortezomib, a first-in-class proteasome inhibitor), an immunomodulatory agent and an alkylating agent.Says that preliminary results suggest that the combination of TH-302 with dexamethasone is active in some heavily pretreated patients who stop responding to conventional therapy.Says that thirteen patients were evaluable for response.Says that two patients achieved a partial response and three patients achieved a minimal response, with the combination of the two types of responses comprising a clinical benefit rate of 38 pct.Says that seven patients had stable disease and one patient had progressive disease.Says that one patient with a minimal response continues to receive therapy after about six months. 

Company Quote

3.07
-0.05 -1.60%
19 Dec 2014